Table 2.
Small-molecule therapeutics targeting HSF1 and Hsp90 in disease models.
| Chaperone Target | Drug | Disease Models | References |
|---|---|---|---|
| Hsp90 | geldanamycin | Parkinson's, Huntington's | (Sittler et al. 2001; McLean et al. 2004) |
| NXD30001 | ALS/SOD1G93A,glioblastoma | (Zhu et al. 2010; Cha et al.2014) | |
| alvespimycin | Castration-resistant prostate cancer | (Pacey et al. 2011) | |
| 17-AAG/tanespimycin | Breast cancer | (Banerji et al. 2005; Modi et al. 2011) | |
| IPI-504/retaspimycin hydrochloride | Gastrointestinal stromal tumor, non-small cell lung cancer | (Sequist et al. 2008; Wagner et al. 2013) | |
| STA-1474 | Osteosarcoma | (McCleese et al. 2009) | |
| PU-H71 | Breast cancer | (Caldas-Lopes et al. 2009) | |
| NVP-AUY922 | Several cancer models | (Eccles et al. 2008) | |
| HSF1 | celastrol | ALS/SOD1G93A,Huntington's, Spinal bulbar muscular dystrophy | (Piccioni et al. 2004; Kiaei et al. 2005; Zhang and Sarge 2007) |
| HSF1A | Huntington's, Machado-Joseph | (Neef et al. 2010) | |
| CYT1; CYT2; CYT3,CYT4 | Huntington's | (Zhang et al. 2009) | |
| PR-A1, A3; PR-C1;PR-D1; PR-F1 | Huntington's, cystic fibrosis | (Calamini et al. 2012) |